Our news
ZENEO® Adrenaline: a new innovative formulation
Crossject has developed a new innovative formulation for ZENEO® Adrenaline to strengthen its commercial potential.
Cooperative agreement signed between Crossject and the US Department of Defense
Crossject and the US Department of Defense have signed a cooperative research and development agreement for Zeneo® Midazolam
ZENEO® Midazolam earns the orphan drug designation
The FDA has granted Orphan Drug designation to ZENEO® Midazolam for the treatment of status epileptics.